Literature DB >> 25963018

Do we need randomised trials for rare cancers?

Vinay Prasad1, Andrew Oseran2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25963018     DOI： 10.1016/j.ejca.2015.04.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  4 in total

Review 1.  An overview of the impact of rare disease characteristics on research methodology.

Authors:  Danielle Whicher; Sarah Philbin; Naomi Aronson
Journal:  Orphanet J Rare Dis       Date:  2018-01-19       Impact factor: 4.123

Review 2.  A plea to provide best evidence in trials under sample-size restrictions: the example of pioglitazone to resolve leukoplakia and erythroplakia in Fanconi anemia patients.

Authors:  Florian Lasch; Kristina Weber; Mwe Mwe Chao; Armin Koch
Journal:  Orphanet J Rare Dis       Date:  2017-05-25       Impact factor: 4.123

Review 3.  A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.

Authors:  Michael J Grayling; Munyaradzi Dimairo; Adrian P Mander; Thomas F Jaki
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

4.  A stochastically curtailed two-arm randomised phase II trial design for binary outcomes.

Authors:  Martin Law; Michael J Grayling; Adrian P Mander
Journal:  Pharm Stat       Date:  2020-08-29       Impact factor: 1.894
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.